Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.

The Journal of infectious diseases - 15 May 2024

Smith Robert A, Raugi Dana N, Nixon Robert S, Seydi Moussa, Margot Nicolas A, Callebaut Christian, Gottlieb Geoffrey S

Abstract excerpt

The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti-HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cell Line

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to CD4 gene

Share to HIV Infections

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 38060982
DOI: 10.1093/infdis/jiad562
PMCID: PMC11095534

Genes

CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.PMID 38060982Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing RegimenSemantic proximity Read ↗

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical IsolatesSemantic proximity Read ↗

JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.Semantic proximity Read ↗

Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).Semantic proximity Read ↗

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.Semantic proximity Read ↗

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.Semantic proximity Read ↗

No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.Semantic proximity Read ↗

Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLASemantic proximity Read ↗

In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Semantic proximity Read ↗

Novel inhibitors of human immunodeficiency virus type 2 infectivitySemantic proximity Read ↗

Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid InhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.